PF-08046037

N/A

Report date: 2026/04/24 20:01:59

Base Information

Drug NamePF-08046037

Drug Alias NamePF-08046037SGN-PDL1iT

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate

Mechanisms of ActionAnti-Programmed death-ligand 1Toll like receptor 7 agonists

TargetsProgrammed death-ligand 1Toll like receptor 7

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and NeckCarcinoma, Pancreatic Ductal +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesPuerto Rico

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and NeckCarcinoma, Pancreatic Ductal +[5]

ATC CodeN/A